文档介绍：竞争分析
(1) Source: Investment bank research report.
公司差异化、核心竞争力及比较竞争优势
2
Medicilon: Public Attention
<Outsourcing in Drug Discovery, 2nd Edition> 2006
As one of top 30 international drug discovery CRO companies
As one of top 3 Chinese drug discovery CRO companies (Medicilon, Bridge and Wuxi were featured)
<Globalization of Drug Development: China> (A CHA report) 2006
As one of top 5 CRO companies in China
Wall Street Reporter Telephone Interview (Sept. 18, 2006)
Chemical & Engineering News, SPRUNG FROM MEDICHEM Dec. 20, 2004
Chemical & Engineering News, CHINESE INDUSTRIAL PARKS UP THE ANTE, Oct. 31, 2006
Business - “Shanghai High-Tech Future” Nov. 27, 2006
Chemical & Engineering News, CHINA STRIDES TOWARD GLOBAL PHARMA ROLE, March 12, 2007
Chemical & Engineering News, MEDICILON STRIVES TO KEEP THE PACE, JUNE 9, 2008
Pharmaceutical Executive, Media Center Interviews, Dec, 2009.
Advantage to Work in Medicilon
US FDA GLP compliance toxicology services
Shanghai government authorized platforms for both non-human primate studies and structural biology
Have passed audit by sFDA for more than 10 times
Have served over 150 companies around the world
Finished 9 DMPK package for filing
Finished 740 Pharmacokinetic studies, 30 toxicological studies and 40 cancer xenograft models in 2009
Owns the non-AAALAC and sFDA audited animal facility in Shanghai area
12 rooms
Owns the largest AAALAC accredited animal facility in Shanghai area
with 46 animal rooms
Can house ~300 monkeys and ~300 dogs
Can house mice, rats, dogs, monkeys, hamster, rabbit and guinea-pig
Owns the largest AAALAC accredited animal facility in Shanghai area
4
Global CRO Revenue (Morgan Stanley, 2008)
Global CRO revenue grows 13% annually to US $30 Billion in year 2011
From Morgan Stanley 2008
Global CRO Preclinical Market
From Morgan Stanley 2008
Based on Source: Frost & Sullivan. 2005年全球CRO总金额达到163亿美元，预计2010年将达到360亿美元的规模
From Morgan Stanley 2008
The Chin